Switching from animal to plant-based protein for managing type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of a plant-based diet that partially replaces animal protein on blood sugar levels and health risks in individuals with type 2 diabetes and excess weight. Participants will be randomly assigned to either a control diet based on current diabetes guidelines or a plant-based diet for 24 weeks, while maintaining their usual physical activity levels. Both groups will receive nutritional and medical support, and their adherence will be monitored through monthly phone calls. Clinical, laboratory, and nutritional evaluations will be conducted at the beginning and end of the study to assess outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 and ≤65 years old)
* Diagnosis of Type 2 Diabetes;
* Glycated hemoglobin from 7% to 11%;
* Overweight or obesity (BMI ≥25 kg/m² and \<40 kg/m²);
* Use of any hypoglycemic and insulin;
* Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening;
* Not having undergone dietary intervention in the last 6 months;
* Have the ability to understand and be able to adhere to intervention proposals;
* Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol;

Exclusion Criteria:

* Type 1 diabetes mellitus;
* Retinopathy with vision deficit that limits the activities proposed in the interventions;
* Chronic kidney disease with estimated glomerular filtration \< 30 mL/min per 1.73m²;
* Liver failure, chronic viral hepatitis;
* Grade III or IV heart failure
* Active or progressive neurodegenerative disease;
* Prior stroke that has caused sequelae;
* Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss;
* Chronic treatment with oral or parenteral corticosteroids (\>7 days consecutive treatment) within 4 weeks prior to screening;
* Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening;
* Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening;
* History of active substance abuse (including alcohol) within the last year;
* Thyroid Stimulating Hormone (TSH) outside the normal range;
* Fasting triglycerides ≥ 600 mg/dL;
* Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years;
* Severe psychiatric illness;
* Predisposition or diagnosis of eating disorders;
* Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding;
* Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months;
* Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma;
* Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study;
* Night workers who work after 10pm;
* Being on a vegetarian, vegan or flexitarian diet at the time of recruitment;
* Having undergone bariatric surgery;
* Carriers of the human immunodeficiency virus (HIV);
* Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities;
* Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.

Where it's running

• Hospital de Clínicas de Porto Alegre
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting

Study contacts

• Principal investigator: Fernando Gerchman, PhD — Hospital de Clinicas de Porto Alegre
• Study coordinator: Fernando Gerchman, PhD
• Email: fgerchman@hcpa.edu.br
• Phone: +555133596246

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.